Bird Flu Monitor > Cases Definition of Avian Influenza

JURNAL ATANI TOKYO [JURNAL ATANI TOKYO] Limited laboratory evidence suggesting the presence of Influenza A virus (H5N1), for example: Hemagglutination Inhibitation (HI) test using H5N1 antigen.

Previous [Previous] Will Avian Flu Become Pandemic...

Next [Next] PRO/MBDS> Avian influenza - MBDS region (60): Viet Nam (Ngh...

Some related posts from Technorati and Google.

vetman speaks [vetman speaks] Latest human bird flu suspects: Somewhere else in Indonesia, poultry avian influenza outbreaks continue, with nothing that can be done, as we are still in the “reaction” stage of civilization.

Cat grooming & Cat health[Cat grooming & Cat health] Avian Influenza in Cats: Influenza A subtype H5N1 causes serious disease in poultry and can cross species barriers and infect humans as well as other species. Although cats had been considered resistant to disease from influenza virus infection, domestic cats and large felids are now known to be naturally and experimentally susceptible to infection with highly pathogenic avian influenza virus H5N1.

Pharma news[Pharma news] Journal Of Clinical Investigation: Sept. 18, 2008: Current vaccines for influenza provide protection against specific seasonal influenza A strains and their close relatives, but not against more distant seasonal influenza A viruses and new avian influenza A viruses, such as H5N1, which still poses a real global health concern. However, a team of researchers led by Tao Dong and Andrew McMichael, at Oxford University, United Kingdom, has now generated data that suggest adding a new component to vaccines for influenza might enable them to confer protection against a broad range of avian and seasonal influenza A viruses.

Pathophilia[Pathophilia] Avian Flu Vaccine Is Immunogenic and Safe in Early-Phase Trial: Colorized transmission electron micrograph of avian influenza A H5N1 virus (gold) grown in MDCK cells (green) from CDC/Cynthia Goldsmith.

Exploring Vaccines [Exploring Vaccines] A Vaccine Timeline: The Global Experiment: “poliomyelomalacia”, “polyradiculoneuritis”, “neurological picture similar to that of poliomyelitis”, “polioencephalomyelomalacia”, “lumbal poliomyelomalacia”, “cerebrocortical necrosis (polioencephalomalacia)”, “Lead poisoning in grey-headed fruit bats (Pteropus poliocephalus)”, “multifocal-poliomyelomalacia”, “spinal poliomalacia”, “Polio and high-sulfate diets”, “atypical porcine enterovirus encephalomyelitis: possible interraction between enteroviruses and arsenicals”, “polioencephalomalacia and photosensitization associated with kochia scoparia

mega millions drawing [mega millions drawing] Tamiflu, Oseltamivir Phosphate: Some resistance to oseltamivir has been found in humans infected with the current strain of H5N1. Neuraminidase inhibitors attack the N component of influenza, neuraminidase, a surface antigen on the influenza A and B viruses that .

Avian Flu[Avian Flu] CDC - Updated Interim Guidance for Laboratory Testing of Persons ...:            Serologic testing for influenza H5N1-specific antibody, using appropriately timed specimens, can be considered if other influenza H5N1 diagnostic testing            methods are unsuccessful (for example, due to delays in respiratory specimen collection). Paired serum specimens from the same patient are required for            influenza H5N1 diagnosis: one sample should be tested within the first week of illness, and a second sample should be tested 2-4 weeks later.

H5N1[H5N1] Today: Pandemic preparations are beginning around the world, and it is important for first responders, particularly disaster management personnel, to understand the difference between pandemic and epidemic influenza preparedness. This article will focus on distinguishing between an influenza epidemic and an influenza pandemic and, in light of these distinctions, how to manage the next pandemic with limited resources, particularly the absence of vaccine.

Project Disaster[Project Disaster] Update on Avian Influenza A (H5N1) Virus Infection in Humans: Uncontrolled viral replication, as reflected in the detection of persistent pharyngeal RNA after completion of standard therapy, is associated with a poor prognosis.58 Higher levels of viral replication and slower clearance of infection probably occur in the lower respiratory tract.3 The oral bioavailability of oseltamivir in patients with severe diarrhea or gastrointestinal dysfunction related to influenza A (H5N1) virus infection or those in whom the drug has been administered extemporaneously (e.g., by means of a nasogastric tube) is uncertain. A higher dose of oseltamivir (e.g., 150 mg twice daily in adults) and an increased duration of therapy, for a total of 10 days, may be reasonable, given the high levels of replication of the influenza A (H5N1) virus, observations of progressive disease despite early administration of standard-dose oseltamivir (75 mg twice daily for 5 days in adults) within 1 to 3 days after the onset of the illness, and the proven safety of higher doses in adults with seasonal influenza, especially if there is pneumonic disease at presentation or evidence of clinical progression.62 In mouse models of amantadine-sensitive influenza A (H5N1) virus infection, as compared with monotherapy, the combination of oseltamivir and amantadine significantly increased survival rates and inhibited viral replication in the internal organs.64 No adverse pharmacologic interactions have been shown in humans.65 In areas where influenza A (H5N1) viruses are likely to be susceptible to amantadine, combination treatment with oseltamivir would be reasonable, especially in seriously ill patients.

[Pharmacy online blog] Study Finds Single Dose Of Iomai Patch With Pandemic Flu Vaccine ...: The only FDA-approved vaccine in the United States for the avian influenza H5N1 virus requires two 90-microgram doses, administered 28 days apart, to achieve hemagglutinin inhibition (HI) titers equal to or greater than 40 in 44 percent of vaccinated individuals.

Asbesotosis Disease Blog[Asbesotosis Disease Blog] Avian Flu Treatments and Antiviral Drugs: AVI Biopharma Inc., a producer of antiviral drugs, has established avian influenza H5N1 as a priority within the company. Michael Hubbard, Director of Investor Relations for the company said that, “We are moving as quickly as we can on .

Reflected tags on Technorati: Blog, ,